Načítá se...
Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
We evaluated the occurrence of infusion-associated reactions, severe adverse events and no evidence of disease activity 3 status of a therapeutic course consisting of natalizumab followed by alemtuzumab in paediatric-onset multiple sclerosis. Five paediatric-onset multiple sclerosis (age range 16–17...
Uloženo v:
| Vydáno v: | Mult Scler J Exp Transl Clin |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6747861/ https://ncbi.nlm.nih.gov/pubmed/31555463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217319875471 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|